PTC Therapeutics, Inc. (PTCT) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
62/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinPTCT / S&P 19.73% / 15.20% |
LosePTCT / S&P -42.84% / 15.00% |
LosePTCT / S&P -108.32% / 50.40% |
| 2026-Q10/3 |
LosePTCT / S&P -10.31% / -4.33% |
LosePTCT / S&P -53.34% / 11.30% |
LosePTCT / S&P -135.79% / 27.70% |
| 2025-Q42/3 |
WinPTCT / S&P 23.77% / 2.65% |
WinPTCT / S&P 114.51% / 9.00% |
LosePTCT / S&P -263.64% / 13.40% |
| 2025-Q32/3 |
WinPTCT / S&P 25.66% / 8.12% |
WinPTCT / S&P 97.54% / 4.61% |
LosePTCT / S&P -244.11% / 13.45% |
| 2025-Q21/3 |
LosePTCT / S&P -4.16% / 10.94% |
WinPTCT / S&P 96.00% / 4.83% |
LosePTCT / S&P -210.46% / 10.63% |
| 2025-Q12/3 |
WinPTCT / S&P 12.89% / -4.27% |
WinPTCT / S&P 91.12% / 4.98% |
LosePTCT / S&P -184.77% / 10.57% |
| 2024-Q41/3 |
WinPTCT / S&P 21.67% / 2.41% |
LosePTCT / S&P -13.97% / 5.25% |
LosePTCT / S&P -43.42% / 6.15% |
| 2024-Q32/3 |
WinPTCT / S&P 21.32% / 5.89% |
WinPTCT / S&P 12.84% / 5.89% |
LosePTCT / S&P -31.41% / 6.11% |
| 2024-Q22/3 |
WinPTCT / S&P 5.12% / 4.28% |
WinPTCT / S&P 9.98% / 5.38% |
LosePTCT / S&P -25.15% / 5.12% |
| 2024-Q11/3 |
LosePTCT / S&P 5.55% / 10.56% |
WinPTCT / S&P 20.39% / 5.71% |
LosePTCT / S&P -2.78% / 5.59% |
| 2023-Q42/3 |
WinPTCT / S&P 22.98% / 11.69% |
WinPTCT / S&P 34.20% / 6.81% |
LosePTCT / S&P 7.18% / 7.78% |
| 2023-Q32/3 |
LosePTCT / S&P -44.90% / -3.27% |
WinPTCT / S&P 14.58% / 7.52% |
WinPTCT / S&P 16.09% / -5.03% |
| 2023-Q22/3 |
LosePTCT / S&P -16.04% / 8.74% |
WinPTCT / S&P 32.43% / 9.50% |
WinPTCT / S&P 7.80% / -8.57% |
| 2023-Q13/3 |
WinPTCT / S&P 26.91% / 7.50% |
WinPTCT / S&P 35.31% / 10.77% |
WinPTCT / S&P 7.19% / -15.69% |
| 2022-Q42/3 |
LosePTCT / S&P -23.96% / 7.56% |
WinPTCT / S&P 29.75% / 11.88% |
WinPTCT / S&P 5.12% / -17.99% |
| 2022-Q32/3 |
WinPTCT / S&P 25.31% / -4.88% |
WinPTCT / S&P 41.52% / 13.47% |
LosePTCT / S&P PTCT unavailable / -1.41% |
| 2022-Q22/3 |
WinPTCT / S&P 7.37% / -16.10% |
WinPTCT / S&P 31.01% / 13.71% |
LosePTCT / S&P PTCT unavailable / 11.04% |
| 2022-Q11/3 |
LosePTCT / S&P -6.33% / -4.60% |
WinPTCT / S&P 32.28% / 15.97% |
LosePTCT / S&P PTCT unavailable / 42.23% |
| 2021-Q41/3 |
LosePTCT / S&P 7.04% / 11.03% |
WinPTCT / S&P 41.45% / 15.00% |
LosePTCT / S&P PTCT unavailable / 96.40% |
| 2021-Q31/3 |
LosePTCT / S&P -11.97% / 0.58% |
WinPTCT / S&P 37.35% / 10.77% |
LosePTCT / S&P PTCT unavailable / 69.42% |
| 2021-Q21/3 |
LosePTCT / S&P -10.73% / 8.55% |
WinPTCT / S&P 51.55% / 6.58% |
LosePTCT / S&P PTCT unavailable / 51.81% |
| 2021-Q11/3 |
LosePTCT / S&P -22.42% / 6.17% |
WinPTCT / S&P 33.82% / -1.06% |
LosePTCT / S&P PTCT unavailable / 7.39% |
| 2020-Q42/3 |
WinPTCT / S&P 30.55% / 12.15% |
WinPTCT / S&P 24.04% / -3.72% |
LosePTCT / S&P PTCT unavailable / -33.42% |
| 2020-Q31/3 |
LosePTCT / S&P -7.86% / 8.93% |
WinPTCT / S&P 20.72% / -2.04% |
LosePTCT / S&P PTCT unavailable / -27.10% |
| 2020-Q21/3 |
LosePTCT / S&P 13.74% / 20.54% |
WinPTCT / S&P 11.59% / -0.46% |
LosePTCT / S&P PTCT unavailable / -27.11% |
| 2020-Q12/3 |
WinPTCT / S&P -7.12% / -19.60% |
WinPTCT / S&P 22.65% / 3.47% |
LosePTCT / S&P PTCT unavailable / -14.75% |
| 2019-Q42/3 |
WinPTCT / S&P 42.02% / 9.07% |
WinPTCT / S&P 15.96% / 5.36% |
LosePTCT / S&P PTCT unavailable / 2.99% |
| 2019-Q31/3 |
LosePTCT / S&P -24.84% / 1.70% |
WinPTCT / S&P 15.77% / 5.02% |
LosePTCT / S&P PTCT unavailable / 0.21% |
| 2019-Q22/3 |
WinPTCT / S&P 19.55% / 4.30% |
WinPTCT / S&P 14.04% / 6.64% |
LosePTCT / S&P PTCT unavailable / 8.65% |
| 2019-Q11/3 |
LosePTCT / S&P 9.67% / 13.65% |
WinPTCT / S&P 17.13% / 8.12% |
LosePTCT / S&P PTCT unavailable / 14.29% |
| 2018-Q41/3 |
LosePTCT / S&P -26.98% / -13.52% |
WinPTCT / S&P 36.19% / 9.05% |
LosePTCT / S&P PTCT unavailable / 18.23% |
| 2018-Q32/3 |
WinPTCT / S&P 39.34% / 7.71% |
WinPTCT / S&P 81.15% / 10.21% |
LosePTCT / S&P PTCT unavailable / 19.06% |
| 2018-Q22/3 |
WinPTCT / S&P 24.65% / 3.43% |
WinPTCT / S&P 99.44% / 9.03% |
LosePTCT / S&P PTCT unavailable / 14.46% |
| 2018-Q12/3 |
WinPTCT / S&P 62.23% / -0.76% |
WinPTCT / S&P 147.80% / 7.68% |
LosePTCT / S&P PTCT unavailable / 12.46% |
| 2017-Q41/3 |
LosePTCT / S&P -16.64% / 6.64% |
WinPTCT / S&P 135.04% / 7.03% |
LosePTCT / S&P PTCT unavailable / 13.82% |
| 2017-Q32/3 |
WinPTCT / S&P 9.17% / 4.48% |
WinPTCT / S&P 101.50% / 5.68% |
LosePTCT / S&P PTCT unavailable / 17.57% |
| 2017-Q22/3 |
WinPTCT / S&P 86.28% / 3.09% |
WinPTCT / S&P 115.10% / 4.83% |
LosePTCT / S&P PTCT unavailable / 17.74% |
| 2017-Q11/3 |
LosePTCT / S&P -9.81% / 6.07% |
WinPTCT / S&P 87.54% / 3.67% |
LosePTCT / S&P PTCT unavailable / 13.32% |
| 2016-Q41/3 |
LosePTCT / S&P -22.13% / 3.82% |
WinPTCT / S&P 124.95% / 2.09% |
LosePTCT / S&P PTCT unavailable / 7.05% |
| 2016-Q32/3 |
WinPTCT / S&P 99.57% / 3.85% |
WinPTCT / S&P 91.46% / 0.20% |
LosePTCT / S&P PTCT unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | PTCT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 45.57% | 20.78% |
| Annualized return | 45.57% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | PTCT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 61.52% | 83.14% |
| Annualized return | 10.06% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | PTCT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 821.82% | 319.30% |
| Annualized return | 24.87% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |